2026-2034年全球淚囊炎治療市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，淚囊炎治療市場規模將從 2025 年的 5,201 萬美元達到 8,756 萬美元，並預計從 2026 年到 2034 年將以 5.96% 的複合年成長率成長。

由於眼部感染疾病和淚道疾病的發生率不斷上升，全球淚囊炎治療市場正在擴大。淚囊炎是指淚囊的感染疾病，通常由淚道阻塞引起。治療通常包括使用抗生素和抗發炎藥物，在某些情況下，還需要手術介入以恢復正常的淚液排放。

市場成長的主要促進因素之一是人們對眼部健康和早期診斷重要性的認知不斷提高。醫療服務可近性的改善使更多患者能夠及時接受眼部感染疾病的治療。此外，微創手術技術的進步也提高了治療效果。

隨著醫療機構更加重視眼科專科醫療服務，淚囊炎治療市場預計將會成長。眼科醫學技術的進步和診斷技術的改進將有助於早期發現和有效治療。此外，發展中地區醫療基礎設施的擴張也將促進市場成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球淚囊炎治療市場：依治療方法分類

• 市場分析、洞察與預測
• 外科手術
• 藥物

第5章：全球淚囊炎治療市場：依適應症分類

• 市場分析、洞察與預測
• 慢性淚囊炎
• 急性淚囊炎
• 先天性淚囊炎

第6章：全球淚囊炎治療市場：依通路分類

• 市場分析、洞察與預測
• 向醫療機構銷售
• 零售銷售

第7章：全球淚囊炎治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc.（Allergan）
  • Alcon Inc
  • Aurolab
  • Bausch Health Companies Inc
  • Bayer AG
  • BVM Medical Limited
  • F. Hoffmann-La Roche Ltd（Genentech Inc.）
  • FCI Ophthalmics
  • Gunther Weiss Scientific Glassblowing Co. Inc
  • Heart Medical Europe BV
  • Kaneka Corporation
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc

The Dacryocystitis Treatment Market size is expected to reach USD 87.56 Million in 2034 from USD 52.01 Million (2025) growing at a CAGR of 5.96% during 2026-2034.

The global dacryocystitis treatment market is growing due to the increasing prevalence of eye infections and tear duct disorders. Dacryocystitis is an infection of the tear sac that occurs when the tear duct becomes blocked. Treatment typically includes antibiotics, anti-inflammatory medications, and in some cases surgical procedures to restore proper tear drainage.

One of the main drivers of the market is the rising awareness about eye health and the importance of early diagnosis. Improved access to ophthalmic healthcare services has enabled more patients to receive timely treatment for eye infections. Additionally, advancements in minimally invasive surgical procedures are improving treatment outcomes.

Looking ahead, the dacryocystitis treatment market is expected to grow as healthcare providers focus more on specialized eye care services. Technological advancements in ophthalmology and improved diagnostic techniques will support early detection and effective treatment. Increasing healthcare infrastructure in developing regions will also contribute to market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

• Surgery
• Medication

By Indication

• Chronic Dacryocystitis
• Acute Dacryocystitis
• Congenital Dacryocystitis

By Distribution Channel

• Institutional Sales
• Retail Sales

COMPANIES PROFILED

• AbbVie Inc Allergan, Alcon Inc, Aurolab, Bausch Health Companies Inc, Bayer AG, BVM Medical Limited, F HoffmannLa Roche Ltd Genentech Inc, FCI Ophthalmics, Gunther Weiss Scientific Glassblowing Co Inc, Heart Medical Europe BV, Kaneka Corporation, Merck Co Inc, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DACRYOCYSTITIS TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Medication Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DACRYOCYSTITIS TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Chronic Dacryocystitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Acute Dacryocystitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Congenital Dacryocystitis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DACRYOCYSTITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Institutional Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DACRYOCYSTITIS TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Treatment
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Treatment
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Treatment
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Treatment
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Treatment
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL DACRYOCYSTITIS TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc. (Allergan)
  • 9.2.2 Alcon Inc
  • 9.2.3 Aurolab
  • 9.2.4 Bausch Health Companies Inc
  • 9.2.5 Bayer AG
  • 9.2.6 BVM Medical Limited
  • 9.2.7 F. Hoffmann-La Roche Ltd (Genentech Inc.)
  • 9.2.8 FCI Ophthalmics
  • 9.2.9 Gunther Weiss Scientific Glassblowing Co. Inc
  • 9.2.10 Heart Medical Europe BV
  • 9.2.11 Kaneka Corporation
  • 9.2.12 Merck & Co. Inc
  • 9.2.13 Novartis AG
  • 9.2.14 Pfizer Inc
  • 9.2.15 Regeneron Pharmaceuticals Inc